3 / 49
•
SELECT and RADIANT have
suggested a trend of improving DFS
of erlotinib as adjuvant therapy for
patients with activating mutation
2,3
.
Abstract ID: 8717
1. Douillard, et al. Lancet Oncol 2006; 7: 719–27; 2. Pennell, et al. J Clin Oncol. 32, no. 15_suppl (May 2014) 7514-7514; 3. Kelly, et al. J Clin Oncol. 2015 Dec 1;33(34):4007-14; 4. IALT Collaborative Group, N Engl J Med
2004;350:351-60; 5. Ou, et al. J Thorac Oncol. 2010 Jul;5(7):1033-41
RADIANT: DFS in EGFR mut+ subgroup
0
0.2
0.4
0.6
0.8
1.0
0
6
12
18
24
30
36
42
48
54
60
66
Time (Months)
DFS
HR
：
0.61
（
95% CI, 0.38-0.98
）
Erlotinib
Placebo
28.5
46.4
SELECT: DFS
Time (years)
1.0
0.8
0.6
0.4
0.2
0.0
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
2-year DFS 89%
DFS
Ensayos clínicos adyuvancia. TKI vs No TKI. En subgrupo mutados: tendencia a mejoría en DFS